Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart, Inc. (OTCQX: VXRT) is a clinical-stage biotechnology company developing oral recombinant vaccines delivered as pills, and its news flow reflects progress across multiple vaccine programs and corporate developments. The company regularly issues updates on its clinical trials for oral pill vaccine candidates targeting coronavirus, norovirus and influenza, as well as a therapeutic HPV vaccine candidate that it identifies as its first immune-oncology program.
Readers following Vaxart news can expect detailed reports on clinical data from its oral vaccine platform. For example, the company has announced Phase 1 results for a bivalent norovirus pill vaccine in lactating women, describing safety, tolerability and increases in norovirus-specific IgA in serum and breast milk, along with evidence of norovirus-specific IgA in infant stool. Vaxart has also highlighted data from second-generation norovirus constructs showing stronger blocking antibody responses and robust fecal IgA increases, and has presented these findings at scientific conferences such as the International Calicivirus Conference, World Vaccine Congress and IDWeek.
Vaxart’s news also covers its COVID-19 oral pill vaccine program, including enrollment and follow-up in a large Phase 2b trial funded under a Project NextGen/BARDA contract, and regulatory and funding updates such as a stop work order that delimited certain activities while maintaining support for follow-up of enrolled participants. In addition, the company has reported on an exclusive, worldwide license and collaboration agreement with Dynavax Technologies Corporation for its oral COVID-19 vaccine candidate, outlining the structure of upfront payments, an equity investment, and potential milestones and royalties.
Beyond clinical and partnership news, Vaxart issues releases on corporate actions, including stock listing changes, governance matters and capital markets events such as conference presentations and investor calls. Investors and observers can use this news feed to track the evolution of Vaxart’s oral vaccine platform, key trial readouts, collaboration milestones and changes in its trading venue and cost management initiatives.
Vaxart (OTCQX: VXRT) published Phase 1, double-blind, placebo-controlled data showing a single-dose oral bivalent norovirus vaccine was safe and well-tolerated in lactating women and induced norovirus-specific antibodies in serum and breast milk.
The study reported norovirus-specific IgA in breastfed infants' stool that correlated with breast milk IgA, suggesting passive transfer of mucosal immunity to infants. Results were published in npj Vaccines on Jan 15, 2026.
Vaxart (OTCQX: VXRT) will present at the virtual Global BioInnovation Forum on Tuesday, January 13, 2026. Senior leaders speaking are Steven Lo (CEO), Sean Tucker, Ph.D. (Founder & Chief Scientific Officer) and James F. Cummings, M.D. (Chief Medical Officer).
The presentation is scheduled for 11:30am PT / 2:30pm ET. A live webcast will be available via the company's investor relations website and will remain accessible for 30 days after the event.
Vaxart (OTCQX: VXRT) reported Q3 2025 results and a business update on Nov 13, 2025. Key items: an exclusive license and collaboration with Dynavax for the oral COVID-19 pill vaccine (upfront $25M plus $5M equity; potential cumulative proceeds up to $700M plus royalties); completion of enrollment of ~5,400 participants in the Phase 2b COVID-19 trial with topline data expected in late 2026 and a 400-person sentinel cohort readout expected in Q1 2026.
Financials: $28.8M cash/investments as of Sept 30, 2025 and runway into Q2 2027; Q3 revenue $72.4M; R&D expense $75.9M; net loss $8.1M.
Vaxart (OTCQX: VXRT) will host two investor webcasts in November 2025. Management will report third quarter 2025 financial results after market close on Thursday, November 13, 2025 and hold a conference call at 4:30 p.m. ET. A stockholder fireside chat is scheduled for Tuesday, November 18, 2025 at 4:30 p.m. ET / 1:30 p.m. PT to answer shareholder questions.
Both events will be webcast on the company website and replayed afterward. Investors can call in using the provided domestic and international numbers for the Nov. 13 call, and may submit questions in advance to ir@vaxart.com or via the webcast portal.
Dynavax (NASDAQ: DVAX) reported Q3 2025 results and announced a new $100 million share repurchase program on Nov 5, 2025. HEPLISAV-B quarterly net product revenue was $90.0M, up 13% YoY, with U.S. total market share ~46% and retail share ~63%. Full-year HEPLISAV-B guidance remains $315–$325M. GAAP net income was $26.9M and adjusted EBITDA was $35.5M for Q3. Cash, cash equivalents and marketable securities totaled $647.8M at Sept 30, 2025. Dynavax entered an exclusive license with Vaxart for an oral COVID-19 vaccine (upfront $25M + $5M equity; $50M contingent payment after Phase 2b), and presented positive topline Phase 1/2 shingles data for Z-1018 at IDWeek.
Dynavax (Nasdaq: DVAX) entered an exclusive worldwide license for Vaxart's oral COVID-19 vaccine program on Nov 5, 2025, paying a $25M upfront license fee plus a $5M equity investment. Vaxart will fund and run the ongoing Phase 2b trial (≈5,400 participants) through an EOP2 meeting with FDA; topline data are expected in late 2026. After the Phase 2b readout Dynavax may elect to assume development, paying an additional $50M and potential milestones up to $195M (regulatory) and $425M (sales) plus low‑to‑mid‑teens royalties.
Vaxart (OTCQX: VXRT) will present research on its second-generation norovirus oral pill vaccine candidate at IDWeek 2025 in Atlanta, held October 19–22, 2025.
The presentation, titled “An Open-Label Phase 1 Clinical Trial Demonstrating Improved Immune Responses to Norovirus Strains GI.1 and GII.4 from a Next Generation Oral Bivalent Vaccine Candidate”, is scheduled for Monday, October 20, 2025, 1:45 PM–3:00 PM ET in room B401-B402 and will be delivered by Nicholas J. Bennett, MBBChir, PhD.
Vaxart (OTCQX: VXRT) will present clinical updates on its oral norovirus and COVID-19 pill vaccine programs at World Vaccine Congress Europe 2025 in Amsterdam on October 13–16, 2025. Two presentations by Dr. Sean Tucker will cover a bivalent oral norovirus vaccine with recent immunogenicity improvements and a clinical update on the oral COVID-19 vaccine covering Phase 1 to Phase 2 data.
The company highlights that its oral recombinant pill platform has generated both systemic and mucosal immune responses and shown a favorable safety and tolerability profile in clinical trials, positioning these programs as ongoing clinical-stage efforts toward potential global public-health solutions.
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company specializing in oral recombinant pill vaccines, has announced the withdrawal of its reverse stock split proposal. CEO Steven Lo emphasized that the company will maintain frequent stockholder communication while focusing on advancing their oral pill vaccine platform technology.
The decision comes after receiving constructive feedback from stockholders, with management expressing commitment to creating long-term value through their proprietary vaccine delivery platform development.
Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant pill vaccines, has appointed W. Mark Watson as Lead Independent Director. Watson, a Certified Public Accountant with over 50 years of experience, including 40+ years at Deloitte, has served on Vaxart's Board since August 2022.
The company is implementing two significant governance changes: appointing Watson as Lead Independent Director and adopting a Director stock ownership policy to align Board interests with stockholders. Additionally, Vaxart is actively seeking stockholder approval for a reverse stock split, with voting deadline set for September 18, 2025, at 11:59 p.m. ET. The special stockholder meeting will be held virtually on September 19, 2025, at 8:30 a.m. PT.
FAQ
What is the current stock price of Vaxart (VXRT)?
What is the market cap of Vaxart (VXRT)?
